Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The interplay between cancer type, panel size and tumor mutational burden threshold in patient selection for cancer immunotherapy.

PLoS computational biology - 1 Nov 2020

Golkaram Mahdi, Zhao Chen, Kruglyak Kristina, Zhang Shile, Bilke Sven

Abstract excerpt

The tumor mutational burden (TMB) is increasingly recognized as an emerging biomarker that predicts improved outcomes or response to immune checkpoint inhibitors in cancer. A multitude of technical and biological factors make it difficult to compare TMB values across platforms, histologies, and treatments. Here, we present a mechanistic model that explains the association between panel size, histology, and TMB...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Computational Biology

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Exome Sequencing

Share to Immunotherapy

Share to Neoplasms

Share to Patient Selection

Share to Treatment Outcome

Share to Tumor Burden

Source

Open in PubMed Open full text

Identifiers

PMID: 33166276
DOI: 10.1371/journal.pcbi.1008332
PMCID: PMC7676656

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The interplay between cancer type, panel size and tumor mutational burden threshold in patient selection for cancer immunotherapy.PMID 33166276Read ↗

Size matters: Dissecting key parameters for panel‐based tumor mutational burden analysisSemantic proximity Read ↗

Quantifying potential confounders of panel-based tumor mutational burden (TMB) measurement.Semantic proximity Read ↗

Tumor Mutational Burden as a Predictive Biomarker in Solid TumorsSemantic proximity Read ↗

Open the Technical Black Box of Tumor Mutational Burden (TMB): Factors Affecting Harmonization and Standardization of Panel-Based TMB.Semantic proximity Read ↗

Tumor Mutation Burden as a Cornerstone in Precision Oncology Landscapes: Effect of Panel Size and Uncertainty in Cutoffs.Semantic proximity Read ↗

Methods of measurement for tumor mutational burden in tumor tissueSemantic proximity Read ↗

Choosing tumor mutational burden wisely for immunotherapy: A hard road to explore.Semantic proximity Read ↗

Expert consensus on the detection and clinical application of tumor mutational burden.Semantic proximity Read ↗

Recommendations for Tumor Mutational Burden Assay Validation and Reporting: A Joint Consensus Recommendation of the Association for Molecular Pathology, College of American Pathologists, and Society for Immunotherapy of Cancer.Semantic proximity Read ↗

Assessments of tumor mutational burden estimation by targeted panel sequencing: A comprehensive simulation analysis.Semantic proximity Read ↗

Aligning tumor mutational burden (TMB) quantification across diagnostic platforms: phase II of the Friends of Cancer Research TMB Harmonization Project.Semantic proximity Read ↗

Designing gene panels for tumor mutational burden estimation: the need to shift from ‘correlation’ to ‘accuracy’Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.